Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients

Susana Chávez-Bueno, Asunción Mejías, Ruth A. Merryman, Naveed Ahmad, Hasan S. Jafri, Octavio Ramilo

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

BACKGROUND: Risk factors for severe respiratory syncytial virus (RSV) disease include prematurity, congenital heart disease, chronic lung disease, and immunocompromised states. There is no consensus concerning the most effective therapy for severe RSV infection in high-risk patients. Palivizumab is approved for prevention of RSV disease, and ribavirin is approved for treatment of RSV infections but its efficacy in high-risk patients has not been conclusively established. METHODS: Retrospective chart review of RSV infected children treated with intravenous palivizumab and ribavirin in a pediatric hospital from 2001 to 2005. RESULTS: Twenty male and 11 female patients with a median age of 23.4 months, hospitalized for RSV infection were treated with intravenous palivizumab from October 2001 through July 2005. Mean dose was 14.93 (SD = 0.68) mg/kg. Twenty-five patients (80%) also received ribavirin, 22 of whom by aerosolization. Common baseline diagnoses were malignancy (n = 15), congenital heart disease (n = 5), and prematurity (n = 5). Included above are 1 cardiac and 6 hematopoietic stem cell transplant recipients. Eighteen (58%) patients had signs of lower respiratory tract infection, 17 were hypoxemic, 10 required intensive care unit (ICU) admission, and 5 were intubated. Twenty-nine (93.6%) patients survived and 2 died. No adverse events attributed to intravenous palivizumab or ribavirin administration were observed. CONCLUSIONS: Treatment of RSV-infected high-risk children with intravenous palivizumab alone or in combination with ribavirin was well tolerated and associated with decreased mortality compared with previous reports.

Original languageEnglish (US)
Pages (from-to)1089-1093
Number of pages5
JournalPediatric Infectious Disease Journal
Volume26
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Respiratory Syncytial Viruses
Ribavirin
Virus Diseases
Pediatrics
Respiratory Syncytial Virus Infections
Heart Diseases
Pediatric Hospitals
Hematopoietic Stem Cells
Respiratory Tract Infections
Lung Diseases
Intensive Care Units
Palivizumab
Chronic Disease
Therapeutics
Transplants
Mortality
Neoplasms

Keywords

  • Immunocompromised children
  • Palivizumab
  • RSV therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. / Chávez-Bueno, Susana; Mejías, Asunción; Merryman, Ruth A.; Ahmad, Naveed; Jafri, Hasan S.; Ramilo, Octavio.

In: Pediatric Infectious Disease Journal, Vol. 26, No. 12, 12.2007, p. 1089-1093.

Research output: Contribution to journalArticle

Chávez-Bueno, Susana ; Mejías, Asunción ; Merryman, Ruth A. ; Ahmad, Naveed ; Jafri, Hasan S. ; Ramilo, Octavio. / Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. In: Pediatric Infectious Disease Journal. 2007 ; Vol. 26, No. 12. pp. 1089-1093.
@article{97e007de56634168ad9c3a789722e176,
title = "Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients",
abstract = "BACKGROUND: Risk factors for severe respiratory syncytial virus (RSV) disease include prematurity, congenital heart disease, chronic lung disease, and immunocompromised states. There is no consensus concerning the most effective therapy for severe RSV infection in high-risk patients. Palivizumab is approved for prevention of RSV disease, and ribavirin is approved for treatment of RSV infections but its efficacy in high-risk patients has not been conclusively established. METHODS: Retrospective chart review of RSV infected children treated with intravenous palivizumab and ribavirin in a pediatric hospital from 2001 to 2005. RESULTS: Twenty male and 11 female patients with a median age of 23.4 months, hospitalized for RSV infection were treated with intravenous palivizumab from October 2001 through July 2005. Mean dose was 14.93 (SD = 0.68) mg/kg. Twenty-five patients (80{\%}) also received ribavirin, 22 of whom by aerosolization. Common baseline diagnoses were malignancy (n = 15), congenital heart disease (n = 5), and prematurity (n = 5). Included above are 1 cardiac and 6 hematopoietic stem cell transplant recipients. Eighteen (58{\%}) patients had signs of lower respiratory tract infection, 17 were hypoxemic, 10 required intensive care unit (ICU) admission, and 5 were intubated. Twenty-nine (93.6{\%}) patients survived and 2 died. No adverse events attributed to intravenous palivizumab or ribavirin administration were observed. CONCLUSIONS: Treatment of RSV-infected high-risk children with intravenous palivizumab alone or in combination with ribavirin was well tolerated and associated with decreased mortality compared with previous reports.",
keywords = "Immunocompromised children, Palivizumab, RSV therapy",
author = "Susana Ch{\'a}vez-Bueno and Asunci{\'o}n Mej{\'i}as and Merryman, {Ruth A.} and Naveed Ahmad and Jafri, {Hasan S.} and Octavio Ramilo",
year = "2007",
month = "12",
doi = "10.1097/INF.0b013e3181343b7e",
language = "English (US)",
volume = "26",
pages = "1089--1093",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients

AU - Chávez-Bueno, Susana

AU - Mejías, Asunción

AU - Merryman, Ruth A.

AU - Ahmad, Naveed

AU - Jafri, Hasan S.

AU - Ramilo, Octavio

PY - 2007/12

Y1 - 2007/12

N2 - BACKGROUND: Risk factors for severe respiratory syncytial virus (RSV) disease include prematurity, congenital heart disease, chronic lung disease, and immunocompromised states. There is no consensus concerning the most effective therapy for severe RSV infection in high-risk patients. Palivizumab is approved for prevention of RSV disease, and ribavirin is approved for treatment of RSV infections but its efficacy in high-risk patients has not been conclusively established. METHODS: Retrospective chart review of RSV infected children treated with intravenous palivizumab and ribavirin in a pediatric hospital from 2001 to 2005. RESULTS: Twenty male and 11 female patients with a median age of 23.4 months, hospitalized for RSV infection were treated with intravenous palivizumab from October 2001 through July 2005. Mean dose was 14.93 (SD = 0.68) mg/kg. Twenty-five patients (80%) also received ribavirin, 22 of whom by aerosolization. Common baseline diagnoses were malignancy (n = 15), congenital heart disease (n = 5), and prematurity (n = 5). Included above are 1 cardiac and 6 hematopoietic stem cell transplant recipients. Eighteen (58%) patients had signs of lower respiratory tract infection, 17 were hypoxemic, 10 required intensive care unit (ICU) admission, and 5 were intubated. Twenty-nine (93.6%) patients survived and 2 died. No adverse events attributed to intravenous palivizumab or ribavirin administration were observed. CONCLUSIONS: Treatment of RSV-infected high-risk children with intravenous palivizumab alone or in combination with ribavirin was well tolerated and associated with decreased mortality compared with previous reports.

AB - BACKGROUND: Risk factors for severe respiratory syncytial virus (RSV) disease include prematurity, congenital heart disease, chronic lung disease, and immunocompromised states. There is no consensus concerning the most effective therapy for severe RSV infection in high-risk patients. Palivizumab is approved for prevention of RSV disease, and ribavirin is approved for treatment of RSV infections but its efficacy in high-risk patients has not been conclusively established. METHODS: Retrospective chart review of RSV infected children treated with intravenous palivizumab and ribavirin in a pediatric hospital from 2001 to 2005. RESULTS: Twenty male and 11 female patients with a median age of 23.4 months, hospitalized for RSV infection were treated with intravenous palivizumab from October 2001 through July 2005. Mean dose was 14.93 (SD = 0.68) mg/kg. Twenty-five patients (80%) also received ribavirin, 22 of whom by aerosolization. Common baseline diagnoses were malignancy (n = 15), congenital heart disease (n = 5), and prematurity (n = 5). Included above are 1 cardiac and 6 hematopoietic stem cell transplant recipients. Eighteen (58%) patients had signs of lower respiratory tract infection, 17 were hypoxemic, 10 required intensive care unit (ICU) admission, and 5 were intubated. Twenty-nine (93.6%) patients survived and 2 died. No adverse events attributed to intravenous palivizumab or ribavirin administration were observed. CONCLUSIONS: Treatment of RSV-infected high-risk children with intravenous palivizumab alone or in combination with ribavirin was well tolerated and associated with decreased mortality compared with previous reports.

KW - Immunocompromised children

KW - Palivizumab

KW - RSV therapy

UR - http://www.scopus.com/inward/record.url?scp=36549025031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549025031&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e3181343b7e

DO - 10.1097/INF.0b013e3181343b7e

M3 - Article

C2 - 18043443

AN - SCOPUS:36549025031

VL - 26

SP - 1089

EP - 1093

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 12

ER -